Edelman Joseph's Form 4 filing
Lyra Therapeutics, Inc. (LYRA) · filed Nov 13, 2025
- Accession no.
- 0001193125-25-280481
- Filed
- Nov 13, 2025, 5:07 PM ET
- Trade date
- Nov 11-13, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 6 non-derivative transactions. Open-market sales total $182.5K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Edelman JosephCIK 0001164426 | 10% Owner |
| Perceptive Advisors LLCCIK 0001224962 | 10% Owner |
| Perceptive Life Sciences Master Fund LtdCIK 0001249675 | 10% Owner |
| Perceptive LS (A), LLCCIK 0001797811 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 11, 2025 | Common Stock | SSaleDisposed | −4,783 | $4.31F1 | −$20,636.73 | 161,318 | Indirect | |
| Nov 11, 2025 | Common Stock | SSaleDisposed | −537 | $4.31F1 | −$2,316.94 | 18,122 | Indirect | |
| Nov 12, 2025 | Common Stock | SSaleDisposed | −7,862 | $4.06F5 | −$31,915 | 153,456 | Indirect | |
| Nov 12, 2025 | Common Stock | SSaleDisposed | −883 | $4.06F5 | −$3,584.45 | 17,239 | Indirect | |
| Nov 13, 2025 | Common Stock | SSaleDisposed | −28,597 | $3.90F6 | −$111,531.16 | 124,859 | Indirect | |
| Nov 13, 2025 | Common Stock | SSaleDisposed | −3,213 | $3.90F6 | −$12,531.02 | 14,026 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.25 to $4.61 inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within such range.
Referenced by the price of 2 transactions in Table I.
- F5
The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.90 to $4.27 inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within such range.
Referenced by the price of 2 transactions in Table I.
- F6
The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.90 to $3.91 inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within such range.
Referenced by the price of 2 transactions in Table I.